 |
|
Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Miguel Sogbe, Idoia Bilbao, Francesco P. Marchese, Jon Zazpe, Annarosaria De Vito, Marta Pozuelo, Delia D’Avola, Mercedes Iñarrairaegui, Carmen Berasain, Maria Arechederra, Josepmaria Argemi, Bruno Sangro
Clin Mol Hepatol. 2024;30(2):177-190. Published online 2023 Dec 29 DOI: https://doi.org/10.3350/cmh.2023.0426
|
|
Citations to this article as recorded by
 Exploring the prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma
Ji Eun Han, Hyo Jung Cho
Clinical and Molecular Hepatology.2024; 30(2): 160. CrossRef Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma
Makoto Chuma, Haruki Uojima, Hidenori Toyoda, Atsushi Hiraoka, Yoshitake Arase, Masanori Atsukawa, Norio Itokawa, Tomomi Okubo, Toshifumi Tada, Kazushi Numata, Manabu Morimoto, Makoto Sugimori, Akito Nozaki, Shuichiro Iwasaki, Satoshi Yasuda, Yuichi Koshi
Hepatology International.2024;[Epub] CrossRef Clinical Parameters Work Well as Predictive Factors for Atezolizumab and Bevacizumab Treatment in Hepatocellular Carcinoma
Ji Yeon Lee, Pil Soo Sung
Gut and Liver.2024; 18(4): 558. CrossRef
|